In one of the first studies to evaluate taxanes versus anthracyclines in the neoadjuvant setting, no added clinical benefit in either overall survival (OS) or disease-free survival (DFS) for the simultaneous administration of doxorubicin and docetaxel compared to doxorubicin and cyclophosphamide was observed during a median of 119 months of follow-up. Importantly, this does not exclude the possibility of the occurrence of a smaller benefit than the study was powered to detect, according to researchers.
In this phase 3, multicentre, randomised trial involving 25 centres in the United Kingdom, Ireland, and Belgium, the long-term outcome of women with primary or locally advanced breast cancer who were randomised to receive either doxorubicin and cyclophosphamide (n=181) or doxorubicin and docetaxel (n=182) as primary chemotherapy were compared . The maximum number of cycles was 6 cycles of either doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) administered intravenously every 3 weeks or doxorubicin (60 mg/m2) + docetaxel (75 mg/m2) intravenously every 3 weeks, followed by surgery on completion of chemotherapy. Eligible patients had histology-proven breast cancer with primary tumours ≥3 cm, inflammatory or locally advanced disease, and no evidence of distant metastases, ECOG performance status 0-1, as well as adequate haematologic, renal, and liver function. Patients were evaluated every 3 weeks and tumour response was determined by clinical assessments of bi-dimensionally measurable disease using standard response criteria. The primary endpoint of this study was the overall clinical response rates to primary chemotherapy.
It was shown that the pathologic complete response rate in the breast was 24% for doxorubicin + cyclophosphamide and 21% for doxorubicin + docetaxel, respectively (P=0.61). At a median follow-up of 119 months, no significant difference between treatment groups for OS (P=0.274) and DFS (P=0.327) was detected. The 10-year OS for doxorubicin + cyclophosphamide was 54% (95% CI 47-62%); this was 60% (95% CI 52-67%) for doxorubicin + docetaxel. The 10-year DFS was 49% (95% CI 42-57%) for doxorubicin + cyclophosphamide and 51% (95% CI 43-58%) for doxorubicin + docetaxel.
Metastatic breast cancer accounted for 89% of deaths in patients who were treated with doxorubicin + cyclophosphamide and 86% in those treated with doxorubicin + docetaxel. Oestrogen receptor (ER) and nodal status were independent prognostic factors for DFS and OS (P<0.0005).
1. Stavraka C, et al. P2-16-15. SABCS 2019.
« Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer Next Article
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.